Bristol-Myers Squibb (BMY: Quote) announced after the bell Wednesday that it has suspended study drug administration in an ongoing Phase II study of BMS-986094, a nucleotide polymerase inhibitor in development for the treatment of hepatitis C.
Bristol-Myers Squibb gapped open sharply lower Thursday and slipped further during the second half of the session. The stock closed down by 3.05 at $32.55 on the highest volume of the year and fell to over a 2-month low.
Click here to receive FREE breaking news email alerts for Bristol-Myers Squibb Co. and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com